Eylea injection treatment is a treatment for Advanced Wet Age-Related Macular Degeneration.

Vascular Endothelial Growth Factor (VEGF) is a naturally-occurring protein in the body, and its normal role is to trigger the formation of new blood vessels, supporting the growth of the body’s tissues and organs. However, in certain diseases, such as wet age-related macular degeneration, it is also associated with the growth of abnormal new blood vessels in the eye, which results in scarring and loss of central vision. Eylea works to inhibit the binding and activation of VEGF receptors. Treatments are administered as an intraocular shot. Having regular shots in the eye may take some getting used to, but the treatment is short and pain-free because your eye will be anesthetized.

“The approval of Eylea offers a much-needed new treatment option for patients with wet AMD,” said the chair of the steering committee for the phase 3 trial, Jeffrey Heier, M.D., also a clinical ophthalmologist and retinal specialist at Ophthalmic Consultants of Boston and Assistant Professor of Ophthalmology at Tufts School of Medicine. “Eylea offers the potential of achieving the efficacy we’ve come to expect from current anti-VEGF agents, but with less frequent injections and no monitoring requirements. This may reduce the need for costly and time-consuming monthly office visits for patients and their caregivers.” (https://www.macular.org/eylea-injection-treatment)

Interested in Greenwood Eye Clinic?